Drug intelligence / Profile preview

OC125IgG-CITC-DTPA-153Sm

Development stage: Preclinical
Lead developer: CISBIO
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**OC125IgG-CITC-DTPA-153Sm** is a radiolabeled monoclonal antibody-based radiopharmaceutical, specifically formulated for targeted imaging and/or therapy. It is constructed by conjugating the OC125 monoclonal antibody (an IgG recognizing the CA125 antigen, commonly overexpressed in ovarian carcinoma) with a bifunctional chelator (CITC-DTPA), which allows stable complexation with the therapeutic radionuclide samarium-153 (^153Sm). The antibody targets CA125-positive tumor cells, delivering the radionuclide directly to tumor tissue for imaging or potential radioimmunotherapy. Its mechanism relies on specific antigen binding and targeted irradiation.

Brand names: OC125IgG-CITC-DTPA-153SmOC-125IgG-CITC-DTPA-153SmOC 125IgG-CITC-DTPA-153Sm
Other names: OC125IgG-CITC-DTPA-153SmOC-125IgG-CITC-DTPA-153SmOC 125IgG-CITC-DTPA-153Sm

Targets

MUC16 (Mucin-16)

Beyond the preview

Go deeper on OC125IgG-CITC-DTPA-153Sm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC125IgG-CITC-DTPA-153Sm.

Explore the full profile